Clinical Trial Update: Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating CD45RA-depleted stem cell addback to prevent viral or fungal infections following TCRab/CD19-depleted hematopoietic ste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Aplastic Anemia
• Hemophagocytic Lymphohistiocytosis
• Immunodeficiency
• Leukemia
• Myelodysplastic Syndrome
• Non-hodgkin Lymphoma

Drugs mentioned

• CD45RA-depleted stem cell addback

Snippet

Sponsor: Children's Hospital of Philadelphia | Conditions: Leukemia, High Risk Acute Lymphoblastic Leukemia | Phase 1, Phase 2 | Status: RECRUITING